UK's latest Budget increases R&D investment and tax credit

11 March 2020

Presenting his first Budget today, Britain’s Chancellor of the Exchequer Rishi Sunak announced that research and development investment will be increased by £22 billion ($28.6 billion), making it the fastest and biggest R&D ever R&D spend.

Overall, the Office for Budget Responsibility (OBR) has said that the Budget was “largest giveaway since 1992” and it will add more than £100 billion to public debt by 2024.

Mr Sunak also announced increased tax relief for companies that carry out qualifying R&D, a measure that increases the rate of the R&D expenditure credit from 12% to 13%, which is expected to affect 7,000 firms, will cost £1.2 million.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK